Alzheimer’s Disease

Biogen’s world-class neurology research and development organisation is pushing towards novel approaches for intractable neurodegenerative conditions such as Alzheimer’s disease.

There are currently no treatments to prevent, delay or stop disease progression.  

Alzheimer’s disease is a progressive neurological condition that impairs the thinking and independence of millions of people worldwide.1 More than half a million people in the United Kingdom are living with Alzheimer’s disease, and this figure is set to rise.2

This disease not only impacts quality of life significantly - it is a leading cause of mortality.

Alzheimer’s disease is usually diagnosed in people 65 and older, but it starts earlier with subtle neurological changes occurring years or even decades before symptoms appear.2

Driven by Biogen’s commitment to patients, and innovative scientific research with the goal of defeating neurological diseases, we remain committed to furthering Alzheimer’s disease research and treatment. Biogen aims to help address the unmet needs in this devastating condition, with an emphasis on early-stage disease.

Learn more about our investigational therapies.

 

  1. World Health Organization. Dementia. Available at: www.who.int/news-room/fact-sheets/detail/dementia.
    Last accessed, April 2019.
  2. Alzheimer’s Society. Who gets Alzheimer's disease? Available at: www.alzheimers.org.uk/about-dementia/types-dementia/who-gets-alzheimers-disease#content-start.
    Last accessed, April 2019  
 
 

Biogen-14415    Date of preparation: June 2019